L
Laurent Chiche
Researcher at University of Montpellier
Publications - 195
Citations - 5086
Laurent Chiche is an academic researcher from University of Montpellier. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 34, co-authored 159 publications receiving 4364 citations. Previous affiliations of Laurent Chiche include Aix-Marseille University & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin.
Carmelo Luci,Ana Reynders,Ivaylo I. Ivanov,Céline Cognet,Laurent Chiche,Lionel Chasson,Jean Hardwigsen,Esperanza Anguiano,Jacques Banchereau,Damien Chaussabel,Marc Dalod,Dan R. Littman,Eric Vivier,Elena Tomasello +13 more
TL;DR: The data show that lymphoid tissue–inducer cells and natural killer cells shared unanticipated similarities and emphasize the heterogeneity of NKp46+CD3− cells in innate immunity, lymphoid organization and local tissue repair.
Journal ArticleDOI
Squash trypsin inhibitors from Momordica cochinchinensis exhibit an atypical macrocyclic structure.
Jean-François Hernandez,Jean Gagnon,Laurent Chiche,Tuyet Mai Nguyen,Jean-Pierre Andrieu,Annie Heitz,Thai Trinh Hong,and T. Trân Châu Pham,Dung Le Nguyen +8 more
TL;DR: Three trypsin inhibitors, from the seeds of the squash Momordica cochinchinensis, have been isolated and purified and it was shown that their polypeptide backbones are cyclic, a structure that has never been described in squash TIs.
Journal ArticleDOI
Treatment of Primary Sjögren Syndrome With Rituximab: A Randomized Trial
Valérie Devauchelle-Pensec,Xavier Mariette,Sandrine Jousse-Joulin,Jean-Marie Berthelot,Aleth Perdriger,Xavier Puéchal,Véronique Le Guern,Jean Sibilia,Jacques-Eric Gottenberg,Laurent Chiche,Eric Hachulla,Pierre Yves Hatron,Vincent Goëb,Gilles Hayem,Jacques Morel,Charles Zarnitsky,Jean Jacques Dubost,Jacques-Olivier Pers,Emmanuel Nowak,Alain Saraux +19 more
TL;DR: This multicenter, double-blind, placebo-controlled, randomized trial found that rituximab alleviated some symptoms at week 6 but did not alleviate symptoms or improve global activity score at month 6 in adults with recent-onset or systemic pSS.
Journal ArticleDOI
Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry
Jacques-Eric Gottenberg,Gaël Cinquetti,Claire Larroche,Bernard Combe,Eric Hachulla,Olivier Meyer,Edouard Pertuiset,Guy Kaplanski,Laurent Chiche,Jean-Marie Berthelot,Bruno Gombert,Philippe Goupille,Christian Marcelli,Séverine Feuillet,Jean Leone,Jean Sibilia,Charles Zarnitsky,Philippe Carli,S. Rist,Philippe Gaudin,Carine Salliot,Muriel Piperno,Adeline Deplas,Maxime Breban,Thierry Lequerré,Pascal Richette,Charles Ghiringhelli,Mohamed Hamidou,Philippe Ravaud,Xavier Mariette +29 more
TL;DR: This prospective study shows good efficacy and tolerance of rituximab in patients with pSS and systemic involvement, which is mostly restricted to patients with systemic involvement.
Journal ArticleDOI
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
Alice Tison,Gilles Quere,Laurent Misery,Elisa Funck-Brentano,François-Xavier Danlos,Emilie Routier,Caroline Robert,Yohann Loriot,Olivier Lambotte,Bertille Bonniaud,Camille Scalbert,Sarah Maanaoui,Thierry Lesimple,Stéphanie Martinez,Marie Marcq,Christos Chouaid,Catherine Dubos,Florence Brunet-Possenti,C. Stavris,Laurent Chiche,Nathalie Beneton,Sandrine Mansard,Florian Guisier,Hélène Doubre,François Skowron,François Aubin,Ouidad Zehou,Christophe Roge,Mickaël Lambert,Anne Pham-Ledard,Marie Beylot-Barry,R. Veillon,Nora Kramkimel,Damien Giacchero,Julie De Quatrebarbes,Catherine Michel,Jean-Bernard Auliac,Gilles Gonzales,Chantal Decroisette,Gwenaelle Le Garff,Ioana Carpiuc,Hervé Vallerand,Emmanuel Nowak,Divi Cornec,Marie Kostine,Groupe de cancérologie cutanée,Club Rhumatismes et Inflammations +46 more
TL;DR: This study evaluated the safety and efficacy of ICIs in patients with preexisting autoimmune disease and cancer and found ICIs were safe and effective in both cancer and autoimmune diseases.